ArticleMolecular neurobiology2025
Silencing Hmox1 Attenuates Cerebral Ischemia/reperfusion Injury and Inhibits Inflammation and Ferroptosis Via the PPAR-γ/FABP4 Signaling Pathway.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Histological Insights into the Neuroprotective Effects of Antioxidant Peptides and Small Molecules in Cerebral Ischemia.Molecules (Basel, Switzerland) · 2025Pooled it
- Cardiovascular toxicity of ethyl maltol exposure: a comprehensive investigation from virtual screening to experimental validation.Archives of toxicology · 2026Article
- Epigenetic Mechanisms Regulating Ferroptosis in Ischemic Stroke: From Pathogenesis to Therapeutic Targets.Cellular and molecular neurobiology · 2026Review
- The context-dependent roles of PPAR-γ in adipocyte differentiation and obesity: a master regulator with dual functions.Frontiers in nutrition · 2026Review
- Ginsenoside RK1 inhibits microglial activation and ROS production and alleviates vascular dementia in rats.Journal of clinical biochemistry and nutrition · 2025Article
- Identification of HMOX-1-Targeting Natural Compounds inPharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cerebral ischemia/reperfusion (I/R) may aggravate tissue injury by promoting oxidative stress, inflammation and cell death after ischemic injury. This study aimed to identify cerebral I/R-associated hub genes and to reveal the underlying mechanism on ischemic I/R. Differential expressed genes (DEGs) were identified from the Gene Expression Omnibus (GEO) database, and hub genes were screened from a protein-protein interaction (PPI) network. The I/R rat model was constructed using the middle cerebral artery occlusion and reperfusion (MCAO/R), and Hmox1 was silenced to investigate its effects on I/R injury, inflammation, oxidative stress and ferroptosis. The effects of silencing Hmox1 were also evaluated in OGD/R-treated HT22 cells. The inhibitor of peroxisome proliferator-activated receptor (PPAR)-γ pathway, T0070907, was used to determine the regulation of Hmox1 on the PPAR-γ/fatty acid binding protein 4 (FABP4) pathway. Heme oxygenase 1 (Hmox1), matrix metalloproteinase-13 (Mmp13), CD44 molecule (Cd44), C-C motif chemokine ligand 3 (Ccl3) and serpin family B member 5 (Serpinb5) were selected as hub genes with higher expression in MCAO/R rats. Silencing Hmox1 inhibited cell apoptosis, decreased tumor necrosis factor-α (TNF-α), Interleukin-1β (IL-1β), IL-6, Fe
Indexed as
Identifiers
40261607What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.